Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 1, 2015

BioPharm International

  • BioPharm International-04-01-2015
  • Volume 28
  • Issue 4

Core-Shell Phase Column Increases Reproducibility

Phenomenex’s Kinetex F5 is a pentafluorophenyl propyl core-shell phase column designed to improve reproducibility and reduce method development time.

 

Phenomenex’s Kinetex F5 is a pentafluorophenyl propyl core-shell phase column designed to improve reproducibility and reduce method development time. A combination of polar and non-polar interactions including hydrogen bonding, electrostatic, hydrophobic, aromatic, and steric/planar mechanisms makes the column useful for high performance liquid chromatography (HPLC)/ultra high performance liquid chromatography (UHPLC) development work. The column allows for reversed phase, 2D-LC, hydrophilic interaction liquid chromatography, supercritical fluid chromatography, or 100% aqueous separation modes, while the fluorinated groups and carbon ring structure are ideal for methods that include halogenated, conjugated, or isomeric compounds.

The column is available in 2.6 and 1.7 μm particle sizes. The 2.6 μm version provides comparable performace to sub-2 μm particles for HPLC and UHPLC systems. The 1.7 μm column delivers 20% greater efficiency than fully-porous sub-2 μm products.

Phenomenex
 

Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.